---
title: "Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296651087.md"
description: "Vertex Pharmaceuticals (VRTX) shares rose 1.44% to $548.05, outperforming the broader market's positive session where the S&P 500 and Dow Jones gained. While VRTX closed near its 52-week high, it lagged behind competitors like Krystal Biotech and Arcturus Therapeutics, which saw larger gains. Trading volume was below the 50-day average."
datetime: "2026-08-21T20:36:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296651087.md)
  - [en](https://longbridge.com/en/news/296651087.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296651087.md)
generator: "portal-rs"
---

# Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Vertex Pharmaceuticals Inc. (VRTX) rallied 1.44% to $548.05 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.43% to 7,674.37 and the Dow Jones Industrial Average rising 0.98% to 53,277.01.

Vertex Pharmaceuticals Inc. closed 1.02% below its 52-week high of $553.69, which the company achieved on August 19th.

The stock demonstrated a mixed performance when compared to some of its competitors Friday, as AbbVie Inc. (ABBV) rose 1.20% to $264.96, Krystal Biotech Inc. (KRYS) rose 2.84% to $346.58, and Arcturus Therapeutics Holdings Inc. (ARCT) rose 22.38% to $13.45.

Trading volume (977,552) remained 637,119 below its 50-day average volume of 1.6 M.

Data source: Dow Jones Market Data, FactSet. Data compiled August 21, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

08-21-26 1636ET

### Related Stocks

- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [KRYS.US](https://longbridge.com/en/quote/KRYS.US.md)
- [ARCT.US](https://longbridge.com/en/quote/ARCT.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [The Bull Case For Vertex (VRTX) Could Change Following Upgraded 2026 Guidance And Pipeline Momentum - Learn Why](https://longbridge.com/en/news/296583461.md)
- [$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/295956299.md)
- [Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2](https://longbridge.com/en/news/296129489.md)
- [Vertex Pharmaceuticals Inc Stock (VRTX) Closed Up by 4.48% on Aug 19: Drivers Behind the Movement](https://longbridge.com/en/news/296396039.md)
- [Amundi Has $352,000 Holdings in ANI Pharmaceuticals, Inc. $ANIP](https://longbridge.com/en/news/295757013.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**